Neurology Central

Aimovig™ gains US FDA approval for the preventive treatment of migraine

0
Novartis (Basel, Switzerland) and Amgen (CA, USA) have announced that the US FDA has approved Aimovig™ (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.
To view restricted content, please:
Share:

Leave A Comment